The Long Shadow of Tuberculosis Before Vaccination

For much of human history, tuberculosis (TB) was a pervasive and deadly threat that shaped societies and claimed lives across every continent. In the 19th century, as industrialization drove masses into crowded, unsanitary cities, TB—then commonly called “consumption” because of the way it seemed to consume its victims from within—became the leading cause of death in Europe and North America. The disease, caused by Mycobacterium tuberculosis, claimed roughly one in seven of all deaths in some urban populations, with mortality rates reaching 400 to 500 deaths per 100,000 people annually in major cities like London, Paris, and New York. It did not discriminate by age or class—poets like John Keats, artists like Frédéric Chopin, and laborers in factories and mines all succumbed to its slow, wasting course. The lack of effective treatments meant that isolation and rest were the only options, and sanatoriums offered little more than palliative care: fresh air, nutritious food, and bed rest, which sometimes slowed but rarely halted the disease. The development of a vaccine was not merely a scientific ambition; it was a public health necessity of the highest order, driven by the urgent need to stop a killer that had haunted humanity for millennia.

Before the advent of vaccination, public health measures focused on isolating the sick and improving living conditions, but these efforts were limited in their impact. TB was deeply intertwined with poverty, malnutrition, and overcrowded housing—factors that perpetuated its spread generation after generation. The disease also had a profound cultural and psychological impact, often romanticized in literature as a disease of sensitive souls, yet feared as a slow and stigmatizing death. The urgent search for a scientific solution gained momentum as the germ theory of disease took hold in the late 19th century, offering the first real hope that a preventive measure could be developed to break the cycle of transmission.

The Foundational Discovery: Mycobacterium tuberculosis

Robert Koch’s Landmark Identification

In 1882, German physician Robert Koch achieved a breakthrough that would set the stage for vaccine development and fundamentally alter the course of medical microbiology. Using a novel staining technique involving methylene blue and Bismarck brown, he identified the rod-shaped bacterium that caused tuberculosis and proved it was transmissible through a series of rigorous experiments. Koch’s discovery, presented on March 24, 1882, before a skeptical Berlin audience at the Physiological Society, was the first time a specific microorganism was conclusively linked to a human disease. He demonstrated that the bacillus could be grown in pure culture, injected into animals to reproduce the disease, and then reisolated—fulfilling the postulates he had established for proving causation. This achievement earned him the Nobel Prize in Physiology or Medicine in 1905 and ignited a global race to find a preventive measure. The established link between germ and disease gave scientists a clear target: a vaccine that could train the immune system to recognize and destroy the TB bacillus before it established infection in the lungs or elsewhere.

The Immediate Aftermath: Koch’s Tuberculin

Koch himself attempted to create a vaccine in what would become a cautionary tale about scientific hubris and the dangers of premature claims. In 1890, he announced that a glycerin extract of the bacteria, which he called tuberculin, could both diagnose and treat TB. The medical community greeted this with enormous hope, and thousands of patients were injected with the preparation. However, tuberculin proved to be a therapeutic failure: it caused severe febrile reactions, local inflammation, and did not cure established disease. Worse, in some cases it appeared to accelerate the disease process, leading to rapid deterioration and death. The backlash was severe, damaging Koch's reputation and setting back TB research by creating widespread skepticism about vaccination approaches. Yet tuberculin did have a lasting legacy—it became the basis for the tuberculin skin test (the Mantoux test), still used today to detect latent TB infection by measuring delayed-type hypersensitivity reactions. Koch’s misstep also taught researchers a critical lesson: that a live, weakened whole-cell vaccine might be more effective than a killed or extracted preparation, because it would better mimic the natural infection and induce a more robust and durable immune response.

Development of the Bacillus Calmette-Guérin (BCG) Vaccine

Pioneering Work at the Pasteur Institute of Lille

Two French scientists, Albert Calmette (a physician and microbiologist) and Camille Guérin (a veterinarian and immunologist), began working on a TB vaccine at the Pasteur Institute of Lille in the early 1900s, building on the lessons learned from Koch's failures. They took a fundamentally different approach: they isolated a virulent strain of Mycobacterium bovis, the bovine form of the tuberculosis bacterium that naturally infects cattle but can also cause human disease, and passaged it repeatedly on a bile-potato-glycerin medium. This process of serial subculture was painstaking and labor-intensive, requiring meticulous attention to maintaining sterile conditions and tracking the genetic changes occurring in the bacterium. Over 13 years, from 1908 to 1921, they subcultured the strain 230 times until it lost its ability to cause disease in laboratory animals (guinea pigs and rabbits) while still provoking an immune response. This attenuated, or weakened, live bacterium became the Bacillus Calmette-Guérin (BCG) vaccine—a name that honors the two scientists and stands as one of the most enduring contributions to global public health.

First Human Use and Early Trials

The first human trial of BCG took place in 1921 under circumstances that would be ethically challenging by modern standards. Calmette administered the vaccine orally (a route he believed would mimic natural infection) to a newborn infant whose mother had died of TB shortly after childbirth, and who was at extremely high risk of infection from his grandmother, who had active pulmonary TB. The child remained healthy, living in close contact with his infected grandmother without developing the disease—a remarkable outcome that galvanized further research. Following this success, BCG was given to hundreds of thousands of infants in France, with careful monitoring of safety and efficacy. By 1928, a large-scale controlled trial involving nearly 31,000 children was launched across multiple centers in France. The results, published in 1930, showed that vaccinated children had a 75% reduction in TB mortality compared with unvaccinated controls, a striking effect that silenced many critics. Despite significant opposition from some medical authorities who questioned the safety of a live vaccine and worried about the risk of reversion to virulence, BCG gradually gained acceptance, especially in Europe and later in countries with high TB burdens. The tragic Lübeck disaster of 1930, where 72 infants died after receiving a contaminated batch of BCG that had been accidentally mixed with a virulent strain, set back adoption but also led to improved manufacturing standards and quality control.

How BCG Works at the Immunological Level

BCG is administered intradermally (or historically, orally), and it stimulates a cell-mediated immune response that is remarkably complex and multifaceted. It triggers the production of T-helper 1 (Th1) cells and activates macrophages, which are critical for controlling intracellular pathogens like Mycobacterium tuberculosis that can survive and replicate inside host cells. The vaccine induces a localized infection that mimics a mild, self-limiting case of TB, training the immune system to mount a swift and coordinated attack upon subsequent exposure. This mechanism is particularly effective at preventing disseminated and severe forms of TB, such as tuberculous meningitis and miliary TB (where the infection spreads through the bloodstream to multiple organs), especially in young children under the age of five. The vaccine also induces trained immunity—a form of innate immune memory that provides broader protection against other infections and may explain some of the nonspecific beneficial effects of BCG that have been observed in epidemiological studies.

Public Health Impact: A Century of BCG Vaccination

Global Adoption and Mortality Reduction

The World Health Organization (WHO) included BCG in its Expanded Programme on Immunization in 1974, recommending it for all infants in countries with a high prevalence of TB—a decision that was based on accumulating evidence of its safety and efficacy in preventing severe childhood TB. By the late 20th century, more than 80% of the world’s infants were receiving BCG vaccination annually, making it one of the most widely administered vaccines in history. Studies estimate that BCG has prevented tens of millions of deaths from disseminated childhood TB since its introduction. For example, a comprehensive meta-analysis found that BCG reduces the risk of TB meningitis by 73% and miliary TB by 84% in vaccinated children, translating to hundreds of thousands of lives saved each year. In high-burden settings like sub-Saharan Africa and South Asia, the vaccine has been a cornerstone of childhood survival, dramatically lowering the number of pediatric TB deaths and contributing to the overall decline in under-five mortality rates.

Regional Variations in Efficacy

Not all populations saw equal protection, and this variance has been one of the most puzzling and debated aspects of BCG's performance. Efficacy against pulmonary TB in adults has ranged from 0% to 80% in different trials, a wide spread that has frustrated efforts to use BCG for population-level control of transmission. A famous trial in the southern United States (the “Birmingham” trial) found BCG to be highly effective, with a 75% reduction in TB incidence, while a large trial in South India (the Chingleput trial) showed no protective effect at all—a finding that stunned the global health community and led to decades of investigation. Geographic latitude, prior exposure to environmental mycobacteria (which are abundant in tropical soils and water), and differences in BCG substrains (multiple genetic variants exist due to decades of independent passage in different laboratories) have all been implicated in this variability. Despite this inconsistency, BCG remains in widespread use because of its undeniable impact on severe childhood forms of the disease and its low cost. It also provides some protection against leprosy, caused by Mycobacterium leprae, and has been shown to reduce all-cause infant mortality in some settings, likely through trained immunity effects.

Challenges That Have Persisted for a Century

Incomplete Protection Against Adult Pulmonary TB

BCG’s inability to provide reliable, long-lasting protection against adult pulmonary TB is its greatest limitation and the primary reason why TB remains a global health emergency. Pulmonary TB is the most infectious form of the disease, and its transmission drives the global epidemic, with each untreated case infecting an average of 10 to 15 contacts per year. Adults with smear-positive pulmonary TB (where the bacteria are visible in sputum under a microscope) are the primary source of spread in communities. Because BCG does not prevent infection with M. tuberculosis or reactivation of latent TB in adults—the pool of an estimated 1.7 billion people worldwide who carry the bacteria asymptomatically—vaccination alone cannot interrupt transmission chains. This explains why TB remains a leading infectious killer worldwide, causing an estimated 1.3 million deaths in 2022 alone, despite near-universal infant vaccination in many countries. The lack of an effective adult vaccine is arguably the most critical gap in the global TB control toolkit.

HIV and the Risks of Live Vaccination

BCG is a live vaccine and can cause disseminated BCG disease (BCG-osis) in immunocompromised individuals, particularly infants born to mothers with HIV who may have weakened immune systems from birth. The WHO recommends that HIV-infected children not receive BCG due to the risk of a life-threatening disseminated infection—a recommendation that creates a painful dilemma in high-HIV-prevalence regions like sub-Saharan Africa, where TB burden is also highest and the need for protection is greatest. The incidence of BCG-osis in HIV-infected infants can be as high as 1 in 100, compared with approximately 1 in 1 million in immunocompetent children. To address this critical safety gap, researchers are urgently developing safer, non-live vaccine candidates that can be given to all infants, regardless of HIV status, without the risk of causing disease in the most vulnerable populations.

Drug Resistance and the Need for Better Tools

Multi-drug resistant TB (MDR-TB), defined as resistance to at least rifampicin and isoniazid—the two most powerful first-line drugs—and extensively drug-resistant TB (XDR-TB), which is resistant to even more drugs, have become serious threats to global TB control. Treatment regimens for resistant TB are long (often 9 to 20 months), toxic (causing side effects like hearing loss, kidney damage, and psychiatric disturbances), and extremely expensive (costing thousands of dollars per patient). A more effective vaccine is widely considered the most promising long-term strategy to dramatically reduce the global TB burden, especially in the face of rising antimicrobial resistance that threatens to make TB untreatable in some regions.

Next-Generation Tuberculosis Vaccines in Development

M72/AS01E – A Promising Breakthrough Candidate

One of the most advanced and exciting vaccine candidates is M72/AS01E, developed by GSK (formerly GlaxoSmithKline) in partnership with the Aeras global TB vaccine foundation and later the Bill & Melinda Gates Foundation. It is a protein subunit vaccine containing two M. tuberculosis antigens (Mtb72F and Mtb39A) combined with the powerful AS01E adjuvant system, which contains a toll-like receptor agonist and a saponin-based adjuvant designed to induce a strong and durable cell-mediated immune response. In a phase 2b trial published in the New England Journal of Medicine in 2018, M72/AS01E reduced the progression from latent TB infection to active pulmonary TB in adults by approximately 50% over a follow-up period of three years. This is the first vaccine since BCG to show efficacy against adult pulmonary TB—a milestone that has generated enormous excitement and hope. A phase 3 trial is being planned with the support of the Gates Foundation, and if successful, this vaccine could be a game-changer for global TB control by providing a tool to prevent the most infectious form of the disease in adults.

VPM1002 – A Genetically Modified BCG with Improved Safety and Efficacy

VPM1002 is a genetically modified version of BCG developed by the Max Planck Institute for Infection Biology in Berlin. It expresses listeriolysin, a pore-forming toxin from Listeria monocytogenes, which improves antigen presentation and immune activation by facilitating the escape of bacterial antigens into the cytosol of infected cells—a process that enhances the stimulation of CD8+ T cells, which are important for killing infected cells. The vaccine is designed to be safer for immunocompromised individuals than standard BCG (because the listeriolysin gene is under the control of a promoter that limits expression) and more effective against pulmonary TB. Clinical trials in infants and adults are underway, including a large phase 3 trial in India that aims to enroll thousands of participants. Preliminary results suggest that VPM1002 may offer better protection against pulmonary TB and a reduced risk of disseminated BCG disease in immunocompromised hosts, but further data from ongoing trials are needed to confirm these early findings.

MTBVAC – A Live Attenuated M. tuberculosis Vaccine Designed to Replace BCG

MTBVAC is a genetically attenuated live vaccine derived directly from M. tuberculosis rather than M. bovis, making it a more homologous vaccine that presents a broader range of antigens to the immune system. It contains two independent gene deletions (phoP and fadD26) that render it safely attenuated while preserving a wider repertoire of antigens than BCG, which lost many genes during its decades of passage in culture. In animal models, MTBVAC has shown superior protective efficacy compared with BCG—a finding that has translated into promising early clinical results. It has completed phase 1 and 2a clinical trials in adults and infants in South Africa and Europe, demonstrating a favorable safety profile and robust immunogenicity. This candidate represents a rational, next-generation design that could potentially replace BCG altogether, offering improved protection and safety for all populations.

Other Novel Approaches in the Pipeline

Other strategies being pursued by researchers around the world include viral-vectored vaccines (e.g., ChAdOx1-85A, developed at the University of Oxford using the same chimpanzee adenovirus vector platform used in the Oxford-AstraZeneca COVID-19 vaccine), whole-cell inactivated vaccines (e.g., RUTI, which uses killed M. tuberculosis presented in liposomes to target latency antigens), and immune-based interventions like the TB/FLU-04L vaccine (an influenza vector expressing TB antigens designed for intranasal administration to induce mucosal immunity). Many of these candidates are in early clinical testing, with some showing promise in phase 1 and 2 trials. The global TB vaccine pipeline now includes over 14 candidates in various stages of development—a robust and growing portfolio that reflects a renewed global commitment to ending the TB epidemic through immunization. The WHO's TB vaccine research and development initiative provides an overview of the current landscape and funding priorities.

Conclusion: Vaccination as a Pillar of TB Control

The development of the first TB vaccine—BCG—was a monumental scientific and public health achievement that has saved millions of lives over the past century. For over 100 years, it has protected children from the most devastating forms of tuberculosis and has provided a foundation for modern immunization programs that reach the world's most vulnerable populations. Its limitations, however, have kept TB entrenched as a major global health challenge, with the disease continuing to kill more people than any other infectious disease except COVID-19 in recent years. Today, the world is on the cusp of a new era of TB vaccine development, with multiple candidates aiming to close the gaps left by BCG and offering hope for finally controlling—and potentially eliminating—this ancient scourge. Alongside improved diagnostics (such as molecular tests that can detect drug resistance in hours), shorter treatment regimens (including the 4-month rifapentine-moxifloxacin regimen for drug-sensitive TB), and efforts to address social determinants such as poverty, malnutrition, and overcrowded housing, a more effective vaccine is the single most powerful tool we can imagine to finally reduce TB to a vestige of the past. The legacy of Calmette and Guérin is not a finished chapter; it is the opening of a continuing story that is far from over. The next generation of vaccines, built on the foundation of their pioneering work, may be what finally turns the tide against one of humanity's oldest and most persistent enemies.

For further reading: The World Health Organization provides updated statistics on TB incidence and mortality here. A detailed scientific review of TB vaccines can be found in the StatPearls article on BCG. Clinical trial results for the M72/AS01E candidate are summarized in this New England Journal of Medicine paper. Information on the global TB vaccine pipeline is available from the WHO TB vaccine research page. For a comprehensive overview of drug-resistant TB treatment guidelines, see the CDC's TB treatment resources.